Keith Robison has a perceptive piece riffing off the recent Illumina instrument launch, and ponders whether 2010 will be the year that array-based genomic technologies finally start to die off with the rise of sequencing.
The market certainly seems to think so. Check out the immediate effect on stock prices for Illumina (ILMN) and array manufacturer Affymetrix (AFFX) following the Illumina announcement (both normalised to 0 at the start of the graph):
This comes in the context of long-term stagnation of AFFX stock, while Illumina has exploded over the last five years. Illumina made plenty of money from the array market, but it also established itself as a key player in the emergence of next-generation sequencing. Affymetrix was not as far-sighted.
- Log in to post comments
More like this
A recent paper in Nature Biotechnology reported the first complete human genome to be sequenced using third-generation, single-molecule sequencing technology. The genome sequenced belongs to one Stephen Quake, co-founder of the biotech company Helicos that developed the Heliscope instrument used…
Getting an accurate genome sequence requires that you collect the data at least twice argue Robasky, Lewis, and Church in their recent opinion piece in Nat. Rev. Genetics [1].
The DNA sequencing world kicked off 2014 with an audacious start. Andrew Pollack ran an article in the New York Times…
ScienceBlogling Tara Smith has a great summary of the recent paper reporting high frequencies of multi-drug resistant Staphylococcus aureus in uncooked meat products (S. aureus is the "SA" in MRSA--methicillin resistant S. aureus, so I won't go through the whole paper here (and Maryn McKenna, as…
DrugMonkey asks "Is the NIH trying to get rid of smaller laboratories?" Before I get to my take on the answer, what I'll be talking about is based on private conversations, so I won't be attributing some things to specific people (sorry Ed!). Take this for what it's worth...
I don't think NIH is…
We're moving away from microarrays for gene expression and shifting efforts to using next gen sequencing instead.
To the extent that I don't believe we're planning on printing any more of our arrays and will just exhaust our current supply for collaborators.